Hello, everyone, and how are you this morning? We are doing just fine, thank you, despite a steady downpour that making the Pharmalot campus grounds particularly soggy. Nonetheless, our spirits are sunny. Once again, we will offer a gentle reminder from the Morning Mayor: Every brand new day should be unwrapped like a precious gift. So after you tug on the ribbon, you can peruse a few items of interest we have assembled for you. Hope you have a smashing day …

AbbVie (ABBV) will pay $63 billion to buy Allergan (AGN), the latest megamerger between two pharma giants seeking new ways to grow, STAT reports. For AbbVie, the acquisition may ease investor concerns about long-term growth, since patents expire in a few years on its franchise product, the Humira rheumatoid arthritis treatment. Allergan sells a portfolio of aesthetic drugs, notably Botox, a $3.6 billion seller, but has struggled with pressure from investor over its own growth plans amid a failed move to extend patent life for an eye treatment.

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Your daily dose of news in health and medicine

Privacy Policy